Table 4.
LC patient characteristics
| Characteristics of recipients | Characteristics of donors | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient’s number | Response to vaccine | Age (year) at OLT | Sex | HBsAg (mIU/mL) at OLT | HBsAb at OLT | HBeAg/HBeAb at OLT | HBV DNA (logcopies/mL) at OLT | MELD at OLT | HCC at OLT | Time of vaccinatio n (months post-OLT) | HBsAb (mIU/mL) at vaccine | NA at vaccine | Age at OLT | Sex | Blood relation | ABO compatibility | HBcAb | HBsAb | HBsAb (mIU/mL) |
| 1 | Good | 56 | M | 100 | – | −/+ | <3.7 | 17 | + | 51 | 49 | LAM | 52 | F | – | Compatible | – | – | <0.1 |
| 2 | Good | 48 | M | >2000 | – | +/+ | 3.5 | 20 | + | 24 | 23 | LAM | 46 | F | – | Compatible | + | + | 134 |
| 3 | Good | 44 | M | 100 | – | +/− | <3.7 | 12 | – | 55 | 1 | LAM | 48 | F | + | Identical | + | + | 189 |
| 4 | Good | 50 | M | >2000 | – | +/− | 3.4 | 9 | + | 42 | 25 | LAM + ADV | 48 | F | – | Compatible | + | + | 627 |
| 5 | Good | 54 | M | >2000 | – | −/+ | 3.8 | 15 | – | 40 | 43 | LAM + ADV | 48 | F | – | Compatible | – | – | <0.1 |
| 6 | Good | 57 | M | >2000 | – | −/+ | 2.7 | 15 | + | 45 | 18 | LAM | 53 | F | – | Identical | – | – | <0.1 |
| 7 | Good | 48 | M | 642 | – | +/− | 4.8 | 17 | – | 29 | 7 | LAM | 44 | F | – | Compatible | + | + | 179 |
| 8 | Good | 47 | F | >2000 | – | +/− | 4.5 | 12 | – | 19 | 6 | LAM | 50 | M | – | Compatible | + | + | 1000 |
| 9 | Good | 55 | M | >2000 | – | +/− | 6.1 | 21 | + | 49 | 6 | LAM + ADV | 48 | M | + | Identical | + | + | 133 |
| 10 | Poor | 52 | M | >2000 | – | +/− | 5.3 | 8 | + | 25 | 4 | LAM | 21 | M | + | Compatible | + | + | 1000 |
| 11 | Poor | 62 | M | >2000 | – | −/+ | <2.6 | 8 | + | 13 | 17 | LAM + ADV | 36 | M | + | Identical | – | – | <0.1 |
| 12 | Poor | 39 | M | >2000 | – | +/− | <2.6 | 7 | – | 30 | 169 | LAM | 35 | F | + | Identical | – | – | <0.1 |
| 13 | Poor | 49 | M | 100 | – | −/+ | 4.0 | 21 | + | 107 | 32 | LAM | 22 | F | + | Identical | – | – | <0.1 |
| 14 | Poor | 26 | M | 100 | – | +/− | 5.5 | 20 | + | 75 | 30 | LAM | 53 | M | + | Identical | + | + | 397 |
| 15 | Poor | 54 | F | 100 | – | +/− | 4.6 | 22 | + | 55 | 1 | LAM | 28 | M | + | Identical | – | – | <0.1 |
| 16 | Poor | 50 | M | 160 | – | −/+ | 2.7 | 18 | + | 38 | 6 | LAM | 25 | M | + | Compatible | + | – | <0.1 |
| 17 | Poor | 44 | M | >2000 | – | −/+ | <2.6 | 15 | – | 32 | 14 | LAM | 47 | F | + | Compatible | – | – | <0.1 |
| 18 | Poor | 55 | F | >2000 | – | +/− | 2.8 | 10 | + | 19 | 10 | LAM + ADV | 51 | F | + | Identical | + | + | 44 |
| 19 | Poor | 54 | M | >2000 | – | −/− | <2.6 | 8 | + | 18 | 47 | ETV | 49 | F | – | Compatible | + | + | 1000 |
| 20 | Poor | 63 | M | 1740 | – | −/+ | <2.6 | 12 | – | 17 | 42 | LAM + ADV | 36 | M | + | Identical | – | – | 0.2 |
| 21 | Poor | 58 | M | 35 | – | −/+ | <2.6 | 16 | – | 16 | 19 | ETV | 33 | F | + | Identical | – | – | 0.3 |
| 22 | Poor | 61 | M | >2000 | – | −/+ | 2.9 | 15 | + | 68 | 5 | LAM | 26 | M | + | Identical | – | – | <0.1 |
NA nucleos(t)ide analogue, LAM lamivudine, ADV adefovir dipivoxyl, ETV entecavir, HBcAb anti-HBc antibody, HBsAb anti-HBs antibody